Better Diabetes Care: Consultation Document
We need your help to develop a revised Action Plan for diabetes care. (Scottish Government)
Consensus Guidelines
Designed for the Management of Adults with Diabetes Mellitus across Wales (Welsh Assembly Government)
Child diabetes cases ‘to double’
The number of under-fives in Europe with type 1 diabetes is set to double between 2005 and 2020, say experts (BBC)
Oculus Innovative Sciences Receives FDA Clearance for Microcyn® Skin and Wound Gel
The Rx product, under the supervision of a health care professional, is intended for management of exuding wounds such as leg ulcers, pressure ulcers, diabetic ulcers and for the management of mechanically or surgically debrided wounds (Oculus Innovative Sciences)
NICE short clinical guideline increases treatment options for patients with type 2 diabetes
The new short clinical guideline is a partial update of last year’s clinical guideline “Type 2 Diabetes (Update)” and examines several new and existing treatments for the management of blood glucose levels in individuals with type 2 diabete (NICE)
NICE endorses new drugs for type 2 diabetes
GPs should consider a new drug class, the gliptins, as a second-line option for treating patients with type 2 diabetes, NICE has recommended (PULSE)
GP incentive system delivers disappointing results on diabetes
The GP incentive scheme has not had the dramatic impact on diabetes care that was predicted when it was introduced five years ago, researchers have found (Health Service Journal)
Special issue of Diabetes Voice focuses on women and diabetes
Diabetes Voice, the quarterly magazine of the International Diabetes Federation, has published a special issue focusing on women and diabetes (IDF)
IDF CEO discusses global impact of NCDs
International Diabetes Federation CEO/Executive Director Ann Keeling appeared on May 19 on Voice of America TV – In Focus, where she was interviewed about the impact of non-communicable diseases (NCDs) on the world (IDF)
IBM, UNC join to harness medical data
UNC Health Care has teamed up with IBM to improve the treatment of patients with diabetes and other diseases by analyzing a giant database of medical information (News & Observer)
CombinatoRx’s diabetes drug meets trial goal, shares up
CombinatoRx Inc said its anti-diabetic treatment met its primary goal in a mid-stage trial, sending the biopharmaceutical company’s shares up 39 percent in pre-market trade (Reuters)
Diabetes Drug Shows Promise Against Multiple Sclerosis
A drug currently FDA-approved for use in diabetes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis (Newswise)
Early and Aggressive Initiation of Insulin Therapy for Type 2 Diabetes: What Is the Evidence?
The objective of this review is to present recent clinical evidence in favor of early and aggressive blood-glucose lowering in patients with type 2 diabetes, and, in this context, to discuss and highlight real-world clinical experiences for type 2 diabetes disease management (Clinical Diabetes)
‘I wrote the book I wanted to read’
When teenager Fibi Ward was suddenly diagnosed with diabetes last year she was devastated … So 14-year-old Fibi decided to pen her own book, which she hopes others will find useful (BBC)
The American Diabetes Association Applauds President Obama’s Nomination of Sonia Sotomayor to the Supreme Court
President Obama’s nomination of Federal Appeals Court Judge Sonia Sotomayor to the Supreme Court of the United States affirms that people with diabetes should not be discriminated against and each person with diabetes should be judged based on his or her merits, not on stereotypes or misinformation about diabetes (ADA)
The RISC study
Fasting insulin, a simple and practical measure, may be a stronger and independent contributor to cardio-metabolic risk and atherosclerosis in a healthy population than hyperinsulinemic euglycemic clamp derived insulin sensitivity (European Journal of Endocrinology)
Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
Overall, intensive compared with standard glycaemic control significantly reduces coronary events without an increased risk of death. However, the optimum mechanism, speed, and extent of HbA1c reduction might be different in differing populations (The Lancet)
Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis
Increased awareness of the magnitude and timing of the risk of type 2 diabetes after gestational diabetes among patients and clinicians could provide an opportunity to test and use dietary, lifestyle, and pharmacological interventions that might prevent or delay the onset of type 2 diabetes in affected women (The Lancet)
Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial
Classic markers of macrovascular and microvascular risk were associated with lower extremity amputations in patients with type 2 diabetes. Treatment with fenofibrate was associated with a lower risk of amputations, particularly minor amputations without known large-vessel disease, probably through non-lipid mechanisms (The Lancet)
The Cardiometabolic Risk Initiative
This new activity will enhance the knowledge and skills of the health care professional by providing them with key strategies and case examples to assist them in obtaining optimum patient goals (American Diabetes Association)
Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis
This study suggests that DM patients are not being treated to ADA-suggested targets (Cardiovascular Diabetology)
Type 2 family history, obesity increase insulin secretion role in IGT
We conclude that, in IGT, an increased genetic predisposition for Type 2 diabetes increases the contribution of impaired insulin secretion to its pathophysiology. This effect is enhanced by obesity (Medwire News)
DRWF Open Funding 2010
The Diabetes Research & Wellness Foundation invites the submission of research projects and proposals requiring funding in the field of diabetes (DRWF)
Glycosmedia is also available as an App: